Business Context and Reporting Period
This Form 8-K concerns TradeUP Acquisition Corp., not Estrella Immunopharma, Inc. The reported events began on July 14, 2021, and the IPO closed on July 19, 2021. TradeUP was a special purpose acquisition company formed to pursue an initial business combination.
Financial Metrics and Capitalization
- The company sold 4,000,000 units at $10.00 per unit, generating $40.0 million of gross IPO proceeds.
- Each unit included one common share and one-half of one redeemable warrant. Each whole warrant is exercisable at $11.50 per share.
- The founders purchased 295,000 private placement shares at $10.00 per share, generating $2.95 million of gross proceeds. The Sponsor purchased 236,000 shares and Tradeup INC. purchased 59,000 shares.
- A total of $40.8 million, consisting of $40.0 million from the IPO and $0.8 million from the private placement, was deposited into a U.S.-based trust account. The filing does not explain the difference between the $2.95 million private placement proceeds and the $0.8 million deposited in trust.
- The filing does not provide revenue, operating profit, net income, cash flow, margins, or debt balances because the company was a newly formed SPAC and no operating-period results are reported.
Material Changes and Corporate Actions
- The SEC declared the IPO registration statement effective on July 14, 2021; the IPO closed on July 19, 2021.
- The company adopted an amended and restated certificate of incorporation and entered into underwriting, trust, warrant, registration rights, founder, indemnification, and related agreements.
- Weston Twigg, Tao Jiang, and James Long became directors. Each was determined to be independent under Nasdaq and Exchange Act standards, and Mr. Twigg was designated an audit committee financial expert.
- The company’s board was classified into three director classes with terms expiring at the 2022, 2023, and 2024 annual meetings.
- Founders transferred 10,000 shares to each of the three independent directors. Each director also received a conditional right to purchase an additional 10,000 shares upon completion of a business combination.
Outlook, Risks, Contingencies, and Unusual Items
- Trust-account funds generally may not be released until completion of the initial business combination, certain shareholder redemptions, or redemption of all public shares if no business combination is completed within 18 months after the IPO closing.
- Interest earned on the trust account may be released for franchise and income taxes and trust-administration expenses.
- The private placement shares are subject to transfer restrictions until 30 days after completion of the initial business combination, except for permitted transfers.
- The principal contingency is the company’s ability to identify and complete a qualifying business combination within the applicable 18-month period. The filing provides no specific target, transaction, revenue guidance, or operating forecast.
Investor Verification Items
- Verify the issuer identity: the filing names TradeUP Acquisition Corp., while the request identifies Estrella Immunopharma, Inc.
- Verify the IPO closing date, unit and warrant terms, and the number and price of private placement shares.
- Reconcile the $2.95 million of private placement proceeds with the $0.8 million described as deposited into the trust account.
- Review the amended certificate of incorporation and trust agreement for redemption rights, deadlines, and permitted uses of trust funds.
- Review founder and independent-director share-transfer arrangements, including lockups and conditional purchase rights.